THE TRANSFORMATION OF AXILLARY SURGERY FOR BREAST CANCER

Authors

  • Jian Huang (Corresponding Author) Department of Gland Surgery, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, Guangxi, China , Baise Key Laboratory of Molecular Pathology in Tumors

Keywords:

Breast cancer, Axillary surgery, SLNB, ALND

Abstract

Breast cancer surgery treatment has a century of development from extended radical mastectomy to modified radical mastectomy and then to breast-conserving surgery. Breast cancer surgery tends to be more and more minimally invasive. Axillary surgery is an important part of breast cancer surgery. Sentinel lymph node biopsy (SLNB) is a common surgical procedure, and axillary lymph node dissection (ALND) is the most common choice for patients with positive sentinel lymph nodes. However, ALND has many sequelae for breast cancer patients, such as postoperative lymphedema, abnormal limb sensation and movement, etc. In the past decade, evidence has shown that it is feasible to avoid ALND in breast cancer with positive sentinel lymph nodes. Some scholars have studied that SLNB combined with axillary radiotherapy is equivalent to ALND. In short, axillary surgery is increasingly tending to be minimally invasive and narrow in scope. This study aims to explore the transformation and future development direction of axillary surgery for breast cancer.

References

[1] Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP, Ashikaga T, Weaver DL, Mamounas EP, Jalovec LM, Frazier TG, Noyes RD, Robidoux A, Scarth HMC, Wolmark N. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. The Lancet Oncology. 2010, 11: 927-933. DOI: 10.1016/s1470-2045(10)70207-2

[2] Giuliano AE,Ballman KV, McCall L,Beitsch PD, Brennan MB, Kelemen PR, Ollila DW, Hansen NM, Whitworth PW, Blumencranz PW, Leitch AM, Saha S, Hunt KK, Morrow M. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA. 2017, 318: 918-926. DOI: 10.1001/jama.2017.11470

[3] Fisher B, Redmond C, Fisher ER, Bauer M, Wolmark N, Wickerham DL, Deutsch M, Montague E, Margolese R, Foster R. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med. 1985, 312: 674-681. DOI: 10.1056/NEJM198503143121102

[4] Fisher B, Jeong JH, Anderson S, Bryant J, Fisher ER, Wolmark N. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med. 2002, 347: 567-575. DOI: 10.1056/NEJMoa020128

[5] Krag DN, Weaver DL, Alex JC, Fairbank JT. Surgical resection and radiotocalization of the sentinel lymph node in breast cancer using a gamma probe. Surgical Oncology. 1993, 2: 335- 340.

[6] Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, Yiangou C, Horgan K, Bundred N, Monypenny I, England D, Sibbering M, Abdullah TI, Barr L, Chetty U, Sinnett DH, Fleissig A, Clarke D, Ell PJ. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst. 2006, 98: 599-609. DOI: 10.1093/jnci/djj158

[7] Lyman GH, Giuliano AE, Somerfield MR, Benson AB, 3rd, Bodurka DC, Burstein HJ, Cochran AJ, Cody HS, 3rd, Edge SB, Galper S, Hayman JA, Kim TY, Perkins CL, Podoloff DA, Sivasubramaniam VH, Turner RR, Wahl R, Weaver DL, Wolff AC, Winer EP, American Society of Clinical O. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2015, 23: 7703-7720. DOI: 10.1200/JCO.2005.08.001

[8] Riedel F, Heil J, Golatta M, Schaefgen B, Hug S, Schott S, Rom J, Schuetz F, Sohn C, Hennigs A. Changes of breast and axillary surgery patterns in patients with primary breast cancer during the past decade. Arch Gynecol Obstet. 2019, 299: 1043-1053. DOI: 10.1007/s00404-018-4982-3

[9] Bonneau C, Bendifallah S, Reyal F, Rossi L, Rouzier R. Association of the number of sentinel lymph nodes harvested with survival in breast cancer. Eur J Surg Oncol. 2015, 41: 52-58. DOI: 10.1016/j.ejso.2014.11.004

[10] Goyal A, Newcombe RG, Chhabra A, Mansel RE, Group AT. Factors affecting failed localisation and false-negative rates of sentinel node biopsy in breast cancer--results of the ALMANAC validation phase. Breast Cancer Res Treat. 2006, 99: 203-208. DOI: 10.1007/s10549-006-9192-1

[11] Chinese Anti-Cancer Association Breast Cancer Diagnosis and Treatment Guidelines and Standards (2019 Edition). Chinese Journal of Cancer. 2019, 29: 609-680.

[12] Bourre JC, Payan R, Collomb D, Gallazzini-Crepin C, Calizzano A, Desruet MD, Pasquier D, Bolla M, Fagret D, Vuillez JP. Can the sentinel lymph node technique affect decisions to offer internal mammary chain irradiation? Eur J Nucl Med Mol Imaging. 2009, 36: 758-764. DOI: 10.1007/s00259-008-1034-4

[13] Estourgie SH, Tanis PJ, Nieweg OE, Valdes Olmos RA, Rutgers EJ, Kroon BB. Should the hunt for internal mammary chain sentinel nodes begin? An evaluation of 150 breast cancer patients. Ann Surg Oncol. 2003, 10: 935-941. DOI: 10.1245/aso.2003.02.015

[14] Postma EL, van Wieringen S, Hobbelink MG, Verkooijen HM, van den Bongard HJ, Borel Rinkes IH, Witkamp AJ. Sentinel lymph node biopsy of the internal mammary chain in breast cancer. Breast Cancer Res Treat. 2012, 134: 735-741. DOI: 10.1007/s10549-012-2086-5

[15] Galimberti V, Cole BF, Zurrida S, Viale G, Luini A, Veronesi P, Baratella P, Chifu C, Sargenti M, Intra M, Gentilini O, Mastropasqua MG, Mazzarol G, Massarut S, Garbay J-R, Zgajnar J, Galatius H, Recalcati A, Littlejohn D, Bamert M, Colleoni M, Price KN, Regan MM, Goldhirsch A, Coates AS, Gelber RD, Veronesi U. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23–01): a phase 3 randomised controlled trial. The Lancet Oncology. 2013, 14: 297-305. DOI: 10.1016/s1470-2045(13)70035-4

[16] Sola M, Alberro JA, Fraile M, Santesteban P, Ramos M, Fabregas R, Moral A, Ballester B, Vidal S. Complete axillary lymph node dissection versus clinical follow-up in breast cancer patients with sentinel node micrometastasis: final results from the multicenter clinical trial AATRM 048/13/2000. Ann Surg Oncol. 2013, 20: 120-127. DOI: 10.1245/s10434-012-2569-y

[17] Verheuvel NC, Voogd AC, Tjan-Heijnen VC, Roumen RM. Potential impact of application of Z0011 derived criteria to omit axillary lymph node dissection in node positive breast cancer patients. Eur J Surg Oncol. 2016, 42: 1162-1168. DOI: 10.1016/j.ejso.2016.05.007

[18] Dixon JM, Cartlidge CWJ. Twenty-five years of change in the management of the axilla in breast cancer. Breast J. 2020, 26: 22-26. DOI: 10.1111/tbj.13720

Downloads

Published

2024-01-01

Issue

Vol. 6 No. 2 (2024)

Section

Research Article

DOI:

https://doi.org/10.61784/jpmr3001

How to Cite

Huang, J. (2024). The Transformation Of Axillary Surgery For Breast Cancer. Eurasia Journal of Science and Technology, 6(2), 23-29. https://doi.org/10.61784/jpmr3001